Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

34.22

+1.01 (3.04%)

as of Jun 24, 2026, 8:00:00 pm Market Open.

69 watching

Investor Insights

Jun 24, 2026, 12:00 am

This summary was created by AI, based on 3 opinions in the last 12 months.

Teva Pharmaceutical, represented by the symbol TEVA-N, is currently experiencing a robust demand for GLP (glucose-lowering agents), although the entry of more generics may lead to price declines in this sector. The company has shown a remarkable recovery under its current CEO, boasting a 264% increase since January 2023, suggesting it's on a promising turnaround. Its headquarters are located in Israel, and it holds a strong position as a large-cap pharmaceutical company, ranking #1 in its ADR/CDR universe among international stocks. Following a breakout over $21 in September, Teva has seen significant accumulation over the past six months, although it does not pay dividends. Analysts remain optimistic, with a price target of $34.50.

Consensus

positive

Valuation

undervalued

Similar

Roche, RHHBY

BUY

Israeli based pharmaceutical company. Largest generic drug manufacturer in the world. Most recent quarter was a little lighter than expected. Acquired a US company made the numbers are little bit light. Good opportunity to buy.

BUY

The largest generic pharmaceutical company in the world. Feels the future in pharmaceuticals is in generics. A good buying opportunity.

HOLD

Over the last few years, has done a lot better than the industry. One of the largest generic drugs. Pharmaceutical sector has really gone to sleep.

WAIT

It's getting to have a lot of compition in that space. It's had a wonderful run, but it's getting rich. I would wait maybe a year or two. The sector overall.

BUY

Has been the best performing drug stock for quite awhile so it is natural that there should be some profit-taking. Just in the process of completing another acquisition. Once that is finished, the stock should come back. Still has a lot of upside.

PAST TOP PICK

(A Top Pick Oct 25/05. Up 14%.) The world's largest generic drug manufacturer. In the process of finalising a major acquisition. This is his growth drug stock and uses Pfizer (PFE-N) as his value drug stock. Still likes.

BUY

A growth pharmaceutical. With its latest purchase, it will be the largest generic drug manufacturer in the world. It also develops its own drugs. Has a phenomenal record. Has great growth ahead of them.

BUY

An Israeli based generic drug manufacturer, the largest in the world. Still likes it very much.

Wealthica Track your Stocks in your Watch List

TOP PICK

Likes sectors that are out of favour and are underowned and finding companies that are flourishing despite a difficult environment. This one is a multinational, multi-billion dollar manufacturer, developer and marketer of mostly generic, but some brand name drugs. Have about 140 products in the pipeline waiting approval. Good growth rate.

TOP PICK

In the process of buying Ivax which will make them the world's largest generic drug manufacturer. They have the best pipeline of drugs coming on. Have everything going for them.

TOP PICK

The 2nd largest generic drug manufacturer, and with the last acquisition it will become the largest. Extremely well managed. Over the next few years there are a lot of drug products coming off patent.

TRADE

Primarily involved in the generic pharmaceuticals. Well managed company. Have to be very conscious of the price. A lot of patents are coming off now which is affording an opportunity to the generic companies.

STRONG BUY

Has been a very strong performer. The leading global generic drug company. Stock has gone sideways this year, but 2006/2007 it will be back to some pretty hefty growth levels.

TOP PICK

An Israeli company with most of their operations and sales in North America and Europe. A generic drug producer.

BUY

Pharmaceutical sector did very poorly over the last 2 years, but deceleration in revenue growth has slowed and profitability has started to improve. Look for the strongest perfoming stock in the sector. As Eli Lilly (LLY-N) is performing better, that would be the better of the 2, but would suggest you look at Sanofi-Aventis (SNY-N) which is close to new highs and Teva Pharmaceuticals (TEVA-Q) in generics.

Showing 241 to 255 of 275 entries

Most Recent Experts

Brendan Caldwell

Caldwell Securities

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Joe Terranova

Virtus Investment Partners

Paul Harris, CFA

Harris Douglas Asset Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Teva Pharmaceutical (TEVA)